CRVO CERVOMED INC

CervoMed to Participate in Upcoming Investor Conferences

CervoMed to Participate in Upcoming Investor Conferences

BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company’s Management will participate in the following investor conferences during the month of November:

Sidoti Virtual Micro Cap Conference

Format: Corporate presentation

Date: Thursday, November 14, 2024

Time: 2:30 PM ET

Webcast Link: click

Stifel 2024 Healthcare Conference

Format: Corporate presentation

Date: Tuesday, November 19, 2024

Time: 3:00 PM ET

Webcast Link: click

The webcast of the presentations will be accessible in the Investor section of the CervoMed website .

About CervoMed

CervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with early-stage DLB.

Investor Contact:

PJ Kelleher

LifeSci Advisors



617-430-7579



EN
07/11/2024

Underlying

CRVOCERVOMED INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CERVOMED INC

 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Reports Second Quarter 2025 Financial Results and Provides Co...

CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over 32 weeks, which improved further among patients who have minimal evidence of Alzheimer’s disease (AD) co-pathology (ptau181 < 2.2 pg/mL at screening) At week 32 of the Extension phase, patients treated with neflamapimod demonstrated a significant reduction from baseline in plasma levels of glial fibrillary ac...

August 11, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Co...

CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the CG 45th Annual Growth Conference being held in Boston, MA, on Tuesday, August 12 to Thursday, August 14, 2025. Presentation DetailsFormat: Fireside ChatDate: Tuesday, August 12, 2025Time: 2:00 PM ETWebcast Link: The webcast of th...

August 5, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase S...

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This risk reduction improved to 64% (p=0.0001) among patients who have minimal evidence of AD co-pathology ...

July 28, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 202...

CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025 Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference® (AAIC) 2025 Conference call and webcast to be held Monday, July 28 at 8:00 AM ET BOSTON, July 24, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company will host a conference call...

July 24, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Announces Late-Breaking Presentations at Alzheimer’s Associat...

CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025 BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual and in-person poster presentations at Alzheimer’s Association® International Congress (AAIC) 2025, being held on July 27 – 31, 2025 in Toronto, Canada. The Company will be presenting the results, including new results, from the RewinD-LB Phase 2b stu...

July 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch